Genetic Analysis

DDW offers an opportunity to gain the latest insights in the Gastrointestinal field, while providing valuable networking and partnering opportunities. Genetic Analysis' Head of Commercial, Kari Furu, Christina Casén, SVP Clinical, and Medical and Zuzanna Gulczynska, Product & Marketing Manager, will attend the congress.

GA will use the event to highlight how GA's microbiome testing platform, GA-map®, can be used for the discovery of novel microbiome-based biomarkers and development of new precision medicine strategies. Specifically, GA will showcase its pipeline product, the GA-map® IBD Precision Dx, the first microbiome-based biomarker for early Ulcerative Colitis (UC) patient stratification. The test enables identification of a microbiome profile associated with aggressive disease, thereby providing prognostic guidance and aid in treatment planning.

Genetic Analysis will also contribute to the scientific program during the meeting:

Sunday, May 3 - 8:00 AM

Kari Furu will give a short presentation introducing Genetic Analysis and our work in gut microbiome innovation during a session hosted by the American Gastroenterological Association (AGA) Gut Microbiome Center and Committee for GI Innovation and Technology.

Monday, May 4 - Poster Session (12:30 - 1:30 PM) | Poster Mo1428

Ken Blount (Ferring Pharmaceuticals), together with Christina Casén, will present our collaborative work with Ferring Pharmaceuticals on: "Monitoring Gut Microbiome Restoration in Patients With Antibiotic-Associated C. difficile Infection".

Attendance at DDW provides an important platform to engage with key stakeholders and supports the company's ongoing efforts to advance its microbiome-based diagnostics pipeline.

Visit this link to read more about the DDW congress: https://ddw.org/